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Summary: Most of the novel targeted anticancer agents share clas-
sical characteristics that define drugs as candidates for blood con-
centration monitoring: long-term therapy; high interindividual but 
restricted intraindividual variability; significant drug–drug and drug–
food interactions; correlations between concentration and efficacy/
toxicity with rather narrow therapeutic index; reversibility of effects; 
and absence of early markers of response. Surprisingly though, thera-
peutic concentration monitoring has received little attention for these 
drugs despite reiterated suggestions from clinical pharmacologists. 
Several issues explain the lack of clinical research and development 
in this field: global tradition of empiricism regarding treatment 
monitoring, lack of formal conceptual framework, ethical difficul-
ties in the elaboration of controlled clinical trials, disregard from 
both drug manufacturers and public funders, limited encouragement 
from regulatory authorities, and practical hurdles making dosage 
adjustment based on concentration monitoring a difficult task for 
prescribers. However, new technologies are soon to help us overcome 
these obstacles, with the advent of miniaturized measurement devices 
able to quantify circulating drug concentrations at the point-of-care, 
to evaluate their plausibility given actual dosage and sampling time, 
to determine their appropriateness with reference to therapeutic tar-
gets, and to advise on suitable dosage adjustment. Such evolutions 
could bring conceptual changes into the clinical development of drugs 
such as anticancer agents, while increasing the therapeutic impact of 
population PK-PD studies and systematic reviews. Research efforts 
in that direction from the clinical pharmacology community will 
be essential for patients to receive the greatest benefits and the least 
harm from new anticancer treatments. The example of imatinib, the 
first commercialized tyrosine kinase inhibitor, will be outlined to 
illustrate a potential research agenda for the rational development 
of therapeutic concentration monitoring.
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Summary: In 2025, there will be 1.56 billion people worldwide 
with hypertension. Although evidence-based interventions have 
transformed blood pressure control, public health data show there 
is still poor blood pressure control, and new therapies are still needed. 
Paradoxically, more sophisticated understanding of pathogenesis 
coincides with a decline in licensing of new medicines for hyperten-
sion. Using discoveries from genomics of blood pressure could be 
used to select and validate drug targets, combining expertise in this 
area with model organism phenotyping, experimental medicine, and 
pharmacology alongside medicinal chemistry may assist. To reduce 
the cost, we could utilize the untapped potential of the electronic 
health record for clinical trial delivery, and “real-world” evaluation 
of clinical effectiveness could reduce some of the risks and costs of 
clinical development, allowing a new generation of molecules to be 
generated in an affordable manner.
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Summary: Routine clinical care in hospitals has become more reliant 
on digital technologies over the last decade. There are now a wide 
variety of electronic solutions aimed at improving patient safety and 
optimizing the use of medicines. This focused session will describe 
technologies available at key stages in the prescribing process: the 
decision to prescribe, the prescription generation, and the ongoing 
monitoring of therapy.
To support the decision-making process, prescribing information 
is available in many different point-of-care digital solutions across 
various platforms such as online computerized guidelines and smart-
phone applications. However, there is often overwhelming informa-
tion available to prescribers. Clinical decision support (CDS) tools 
can help because they allow more relevant information, often specific 
for the patient, to be embedded in the clinical workflow. Better still is 
the use of electronic prescribing medication administration (EPMA) 
systems either as standalone systems or as part of a wider electronic 
patient record. Such systems may influence prescribing decisions; 
for example, by promoting efficacious and cost-effective therapy. 
Other steps in the medicines use process can also be targeted by 
novel technologies such as automated dispensing systems and posi-
tive patient identification through barcode medication administra-
tion systems. Electronic medication administration records enable 
the precise monitoring of medication use on an individual patient 
surveillance level through to providing data for hospital-wide medi-
cation management strategies.
Individually, all of these have been shown to effect safe prescrib-
ing. The advantage of combining these technological advances—
which are already available in a limited number of integrated 
systems—cannot be underestimated and will become increasingly 
important to support tomorrow’s prescribers in providing optimal 
patient care.
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Summary: A range of new technologies is about to enable patients to 
produce a steady flow of information about their bodies: for example, 
heartbeat, blood pressure, sugar level, calories spent, temperature, 
sleep pattern. They are seen as useful to improve the quality of life 
and the accuracy of treatment for many patients, especially those with 
chronic diseases. This is probably the case when data are collected 
and analyzed by professionals. But since patients (or persons not 
suffering from any disease) will also be to monitor their own data 
without immediate supervision, there is a risk of misuse and get-
ting lost, that can lead to false or dangerous “homemade” medicine. 
Also, privacy of patients may be in danger. This is not only about 
preventing unauthorized persons from accessing these sets of very 
sensitive data, but probably to protect patients against themselves. 
Indeed, as some of them already post their genetic pattern on social 
networks, disclosing one’s own body’s parameter can potentially 
become a common practice. That would be extremely profitable for 
drug companies to sell their products, for example, or for insurance 
companies looking to filter good risks from bad ones. The lesson to 
be learned is that one should not consider that the data are available 
for any purpose just because the person decided to make his or her 
own data public, something that nobody will be ever able to forbid. 
Unfortunately, current data protection policies still consider data 
made public as… public. In fact, even a perfect protection of privacy 
could not address the problems of a complex relationship between 
information and power. To shed light on this subtle relationship, I will 
use the Michel Foucault’s concept of “biopower.” It will reveal that 
the project of developing techniques to build self-powered patients 
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creates new forms of power with specific characteristics: the need of 
transparent subjects, the participation of patients to the power that 
aims to take control on their own body, and the growing porosity 
between the private and public sectors. First applied to the analysis 
of sexuality, the concept of biopower is nowadays highly relevant 
to analyze this new turn in medicine practices that involve the full 
cooperation and transparency of patients.
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Summary: The treatment of multiple sclerosis as an autoimmune 
disorder has benefited for several years from the progresses of bio-
therapeutics. Since the mid-1990s, interferon beta has been proposed 
as a valuable treatment for certain MS patients due to its immu-
nomodulator properties, followed shortly after by the registration 
of the polypeptide glatiramer acetate. More recently, monoclonal 
antibodies have been developed to target selective components of the 
immune response and provide a selective immunosuppression that 
could treat the disease with an acceptable safety profile. Natalizumab 
was the first of these monoclonal antibodies, and other monoclonal 
antibodies such as rituximab or alemtuzumab, originally developed 
in oncology, have since been repositioned for autoimmune disor-
ders such as MS. However, these molecules, which are very selective 
in their targets, often do not appear so favorable during develop-
ment, and their safety profile could significantly limit their use. More 
recently, the development of monoclonal antibodies has refocused 
more on targeting proteins that play critical roles in the pathophysiol-
ogy of MS, notably on the specific processes of neurotoxicity: these 
antibodies are now in early clinical development and may bring new 
avenues in the treatment of MS.
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Summary: Ever since “modern” pharmacovigilance started in the 
early 1980s, it has gone through changes of various pace introduced 
by new concepts (eg, CIOMS I-V), development of science and meth-
odologies (eg, pharmcoepidemiology), technology (eg, databases), or 
regulatory requirements (eg, risk management, new legislation). Over 
the period of time, methods of data collection and analysis became 
easier, which is helpful, taking into account the fast-growing world’s 
population. However, everyday general medical practice did not 
change much despite great progress in sciences. Large safety data are 
accessible from organized databases in regulatory bodies, industry, 
medical insurance, and other organizations, facilitating their analysis 
and aggregate evaluation, but in many situations, actions are still 
triggered by the assessment of causal associations based on medical 
judgment performed on individual cases or case reports. The future 
of pharmacovigilance should be based on well-thought-through risk 
management combined with risk minimization activities, which will 
reflect preceding appropriate benefit/risk assessment. This can be 
delivered by adequate training in clinical pharmacology, which will 
include good prescribing practices and the development of regulatory 
science either within clinical pharmacology or as a separate discipline. 
In addition, the broad understanding of important safety information 
collected and assessed from population data and in large databases 
should grow and facilitate data-driven scientific decision making.
Clinical pharmacology has an important role at present and in the 
future by providing curricula for HCPs across the world, teaching 
appropriate prescribing, risk management/minimization concepts, 
and contributing to the increase in protection of public health and 
individual patient safety by being much more prominent in the HCP 
training and clinical practice.
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Summary: Every day, European poisons centers (PC) assess poison-
ing risks of thousands of exposures to toxic agents and give advice 
for best-practice medical treatment, triggered by telephone calls from 
medical staff, patients, or caregivers. PC are continuously registering 
all exposure cases in local databases and are analyzing these data to 
detect or verify unusual poisoning events (often involving several or 
many patients) and trends of poisoning.
By this method of toxicovigilance, for example, the Swiss PC 
detected series of unexpected breathing disorders caused by regular 
intended use of 1 of 3 waterproofing spray products in 2003 and, 
more recently in 2012, the GIZ-Nord Poisons Centre in Germany dis-
covered a Ciguatera poisoning series (14 patients) generated by con-
taminated seafood (Red Snapper) purchased in local supermarkets. In 
some of these events, the toxic products identified were removed from 
shops within hours, after notifications of PCs to retail, competent 
regional, or national authorities, prevented many more poisonings.
In the past, unexpected poisoning risks that might have been caused 
by rare exposures and very rare notification to PC may have been 
missed if only single cases were notified to PC, and the cases could not 
been validated with sufficient quality. Today, networks of PC facili-
tate exchange of observations, case reports, and related toxicologic 
knowledge to rapidly confirm new or unusual poisoning risks. With 
help of conveniently new communication tools, several PC networks 
have been founded or intensified in Europe in the last decade. The 
European Association of Poisons Centres and Clinical Toxicologists 
forms the most powerful and Europe-wide expert network.
In 2011, the Public Health Project “Alert System for Health 
Threats” (ASHT, sponsored by the European Commission and the 7 
project partner organizations) had designed and tested a surveillance 
system that can collect a vast number of exposure cases reported to 
PC in real time. This system facilitates the timely concomitant analy-
sis of all cases submitted to detect unusual and hidden poisoning risk 
in a more sensitive way in the near future.
In conclusion, toxicosurveillance of population poisoning risks, 
enabled by PC’s toxicovigilance, has played an important role in 
detecting unexpected poisonings, especially poisonings caused by 
intended use of unsafe products in the past, and will play an even 
more important role in the future powered by rapidly reacting PC 
networks.
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